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A role for B-cell-receptor (BCR) signalling in lymphomagenesis has been inferred by studying immunoglobulin genes in human lymphomas 1, 2 and by engineering mouse models 3 , but genetic and functional evidence for its oncogenic role in human lymphomas is needed. Here we describe a form of 'chronic active' BCR signalling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL). The signalling adaptor CARD11 is required for constitutive NF-kB pathway activity and survival in ABC DLBCL 4 . Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-kB 5 , but the mechanism that engages wild-type CARD11 in other ABC DLBCLs was unknown. An RNA interference genetic screen revealed that a BCR signalling component, Bruton's tyrosine kinase, is essential for the survival of ABC DLBCLs with wild-type CARD11. In addition, knockdown of proximal BCR subunits (IgM, Ig-k, CD79A and CD79B) killed ABC DLBCLs with wildtype CARD11 but not other lymphomas. The BCRs in these ABC DLBCLs formed prominent clusters in the plasma membrane with low diffusion, similarly to BCRs in antigen-stimulated normal B cells. Somatic mutations affecting the immunoreceptor tyrosinebased activation motif (ITAM) signalling modules 6 of CD79B and CD79A were detected frequently in ABC DLBCL biopsy samples but rarely in other DLBCLs and never in Burkitt's lymphoma or mucosaassociated lymphoid tissue lymphoma. In 18% of ABC DLBCLs, one functionally critical residue of CD79B, the first ITAM tyrosine, was mutated. These mutations increased surface BCR expression and attenuated Lyn kinase, a feedback inhibitor of BCR signalling. These findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.
DLBCL is a heterogeneous diagnostic category consisting of molecularly distinct subtypes that differ in gene expression, oncogenic aberrations and clinical outcome 7, 8 . The ABC DLBCL subtype relies on constitutive NF-kB signalling to block apoptosis, but the germinalcentre B-cell-like (GCB) subtype does not 9 . Recurrent CARD11 mutations in ABC DLBCL provided genetic evidence that NF-kB signalling is central to its pathogenesis 5 . However, most ABC DLBCLs have wildtype CARD11 yet nonetheless rely on CARD11 to activate NF-kB signalling 4, 9 .
In normal B cells, CARD11 is engaged during antigenic stimulation of BCR signalling. Antigen specificity of the BCR is provided by surface immunoglobulin, but signalling is mediated by two associated proteins, CD79A (Ig-a) and CD79B (Ig-b) 10 . The CD79A-CD79B heterodimer is a scaffold for the assembly and membrane expression of the BCR and also initiates downstream signalling to the NF-kB, phosphatidylinositol-3-OH kinase, extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase and NF-AT pathways. Engagement of the BCR by antigen induces Src-family kinases to phosphorylate tyrosines in the ITAM motifs of CD79A and CD79B. The tyrosine kinase Syk is activated by binding to the phosphorylated ITAMs, triggering a signalling cascade that involves the tyrosine kinase Bruton's tyrosine kinase (BTK), phospholipase Cc and protein kinase Cb (PKC-b). PKC-b phosphorylates CARD11, causing it to recruit BCL10 and MALT1 into a multiprotein 'CBM' complex that activates IkB kinase (IKK), thereby initiating NF-kB signalling.
A potential role for BCR signalling in ABC DLBCLs with wild-type CARD11 was revealed by an RNA interference screen. Two short hairpin RNAs (shRNAs) targeting the BCR pathway component BTK were highly toxic for an ABC DLBCL line with wild-type CARD11 (OCI-Ly10) but not for one with mutant CARD11 (OCILy3), nor for GCB DLBCL and multiple myeloma lines ( Fig. 1a and Supplementary Fig. 1 ). In subsequent survival assays, a BTK shRNA was toxic for four ABC DLBCL lines with wild-type CARD11 but not for OCI-Ly3 or six GCB DLBCL lines (Fig. 1b) . BTK kinase activity was required for the rescue of ABC DLBCL lines from the toxicity of BTK knockdown (Fig. 1c) .
The role of BTK in BCR signalling prompted us to investigate the reliance of ABC DLBCLs on other BCR pathway components. A CD79A shRNA killed all four ABC DLBCL lines with wild-type CARD11 but not the line with mutant CARD11 or the GCB DLBCL lines (Fig. 2a) . In contrast, a CARD11 shRNA killed all ABC DLBCL lines, and a control shRNA was non-toxic. In the line HBL-1, the knockdown of surface CD79A expression by different shRNAs caused a proportional decrease in surface IgM, implying that the toxicity of CD79A knockdown was due to a loss of surface BCR ( Supplementary Fig. 2a ). CD79B shRNAs were also toxic to ABC DLBCLs, and the degree of CD79B knockdown was proportional to the decrease in surface BCR and to toxicity ( Supplementary Fig.  2b , c). To investigate the role of the immunoglobulin receptor, we developed shRNAs targeting IgM and Ig-k ( Supplementary Fig. 3 ). These shRNAs were also selectively toxic to ABC DLBCLs with wildtype CARD11, establishing a direct role for immunoglobulin in this signalling (Fig. 2b) . The NF-kB pathway is activated by BCR signalling in ABC DLBCLs because knockdown of BTK, CD79A, CD79B and CARD11 decreased the expression of NF-kB target genes and inhibited IKK (Supplementary Fig. 4 ). BCR signalling also activates the phosphatidylinositol-3-OH kinase and ERK MAP kinase pathways in these cells, because CD79A knockdown inhibited phosphorylation of Akt and ERK in addition to IkB-a (Fig. 2c) .
A subsequent focused shRNA screen suggested that other BCR signalling components contribute to chronic active BCR signalling, including Syk, BLNK, phospholipase Cc2 and PKC-b (Supplementary Fig. 5 ). A Syk shRNA killed two ABC DLBCL lines with wild-type CARD11 (HBL-1 and TMD8) but not two others (OCI-Ly10 and U2932), and also had no effect on OCI-Ly3 or GCB DLBCL lines ( Fig. 2a) , despite comparable knockdown ( Supplementary Fig. 6a ). Not only was OCI-Ly10 insensitive to Syk knockdown but it also died with ectopic expression of wild-type but not kinase-dead Syk ( Supplementary Fig. 6b ). A previous study with a Syk inhibitor, R406, concluded that most DLBCLs rely on tonic BCR signalling 11 . However, R406 killed Syk-independent GCB and ABC DLBCL lines (including OCI-Ly10), suggesting that its toxicity in these lines may be due to inhibition of other kinases and not BCR signalling ( Supplementary Fig. 6c ).
We next used total internal reflection fluorescence (TIRF) microscopy to reveal BCRs on the surface of lymphoma lines. In normal mouse B cells, TIRF microscopy revealed that antigen exposure causes BCRs to form clusters with decreased diffusion, leading to BCR signalling 12 . All five ABC DLBCL lines had prominent BCR clusters that were not present in 16 other lines derived from GCB DLBCL, Burkitt's lymphoma or mantle-cell lymphoma (Fig. 2d, f) . BCR clusters were also observed in biopsies from three patients with ABC DLBCL (Supplementary Fig. 7a ). Moreover, the BCRs in ABC DLBCLs diffused less rapidly than those in other lymphoma lines (Fig. 2e, f) . We observed a correlation between BCR clusters and phosphotyrosine accumulation in ABC DLBCL lines, suggesting that these structures may be actively signalling ( Supplementary Fig. 7b ).
Taken together, these findings establish a continuing requirement for proximal BCR signalling in ABC DLBCLs with wild-type CARD11. Because these lines also depend on CARD11, like antigen-activated normal B cells, we refer to this phenomenon as 'chronic active' BCR signalling. We wish to distinguish chronic active BCR signalling from 'tonic' BCR signalling. Tonic BCR signalling promotes cell survival in all mature mouse B cells 13, 14 , but mice deficient in CBM components have relatively normal numbers of mature follicular B cells 15 . It therefore seems likely that CARD11 is not essential for tonic BCR signalling but is required for chronic active BCR signalling. Moreover, chronic active BCR signalling is characterized by BCR clustering, which is not observed in resting mouse B cells that depend on tonic BCR signalling 12 .
To provide genetic evidence of BCR signalling in the pathogenesis of ABC DLBCL, we resequenced genes in the BCR pathway in DLBCL cell lines and biopsies. We identified missense mutations affecting the first tyrosine of the CD79B ITAM motif in two cell lines, HBL-1 (Y196F) and TMD8 (Y196H) (Fig. 3a) . Both lines were heterozygous for this mutation, but more than 90% of the CD79B messenger RNA in HBL-1 was derived from the mutant allele (data not shown). These mutations prompted us to resequence the CD79B ITAM region in 225 DLBCL biopsies. In 18% (29 out of 161) of ABC DLBCLs, the first ITAM tyrosine was replaced by a variety of amino acids as a result of point mutations; in one case, this residue was removed by a three-base-pair deletion (Fig. 3a, b) . Less common were missense mutations in other ITAM residues and deletions that disrupted all or part of the motif. Of 64 GCB DLBCLs, only one had a mutation affecting the first ITAM tyrosine and one other had a different ITAM mutation (L199Q). Overall, the frequency of CD79B ITAM mutations was significantly higher in ABC DLBCL (21.1%) than in GCB DLBCL (3.1%) (P 5 8.9 3 10
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). CD79B ITAM mutations were not present in 20 Burkitt's lymphoma and 16 gastric mucosa-associated lymphoid tissue (MALT) lymphoma biopsies. In six cases of ABC DLBCL, analysis of non-malignant tissue established that the CD79B mutations were somatically acquired by the malignant cells ( Supplementary Fig. 8 ).
The CD79A ITAM region of the ABC DLBCL line OCI-Ly10 has a splice-donor-site mutation 16 causing an 18-amino-acid deletion that removes most of the ITAM, including the second tyrosine. Though OCI-Ly10 was heterozygous for this mutation, more than 90% of the CD79A mRNA was mutated (data not shown). One ABC DLBCL biopsy had a similar splice-site mutation and another had mutations that deleted the entire CD79A ITAM (Fig. 3a) . CD79A mutations were rare among ABC DLBCLs, occurring in 2.9% (2 out of 68) of biopsies.
In mouse B cells, mutations in the CD79A or CD79B ITAM tyrosine residues elevate surface BCR expression by inhibiting receptor internalization 17 . Indeed, GCB DLBCL cells reconstituted with CD79A or CD79B mutants derived from ABC DLBCLs had more surface IgM expression than cells with wild-type isoforms, but this was not true of CD79 ITAM mutations that were not observed in samples from patients (Fig. 3c) . Similarly, ABC DLBCL cells reconstituted with mutant CD79B had higher surface BCR expression than those reconstituted with wild-type CD79B (Fig. 3d) . Interruption of chronic active BCR signalling with the kinase inhibitor dasatinib (see later) increased surface BCR expression in ABC DLBCL cells with wild-type but not mutant CD79B (Fig. 3d) . Hence, one function of the CD79 mutations is to maintain surface BCR expression in the face of chronic active BCR signalling.
We speculated that the CD79B mutations might be genetically selected in ABC DLBCLs for their ability to circumvent negative regulatory circuits that attenuate BCR signalling. Whereas several Src-family tyrosine kinases can initiate BCR signalling, Lyn is unique in mediating negative feedback on BCR signalling 18 . Indeed, Lyndeficient mice succumb to an autoimmune disease that has been traced to BCR hyperactivity 19 . Lyn is required for BCR internalization 20, 21 , suggesting that CD79 mutations might elevate surface BCR expression by inhibiting Lyn. To test this, we knocked down endogenous CD79B expression in HBL-1 and TMD8 cells, both of which harbour a CD79B mutation, and complemented them with exogenous wild-type or mutant CD79B complementary DNAs. Immunoprecipitation of Lyn followed by an in vitro kinase assay showed greater Lyn kinase activity in cells reconstituted with wild-type CD79B (Fig. 3e) . These data suggest a model in which CD79B mutations are selected in ABC DLBCLs to attenuate negative autoregulation by Lyn during chronic active BCR signalling.
The CD79 mutants are not loss-of-function mutants because they prevented death of ABC DLBCL cells caused by knockdown of endogenous CD79 isoforms (Supplementary Fig. 9 ). However, the CD79 mutants were not functionally superior to their wild-type counterparts in this assay (Supplementary Fig. 9 ) and did not spontaneously activate NF-kB when introduced into GCB DLBCL cells, unlike CARD11 mutants 5 (data not shown). We therefore propose that the CD79 ITAM mutations may be selected early in the genesis of the malignant clone, perhaps to allow it to respond abnormally well to a self or foreign antigen (Supplementary Fig. 10 ). In this regard it is notable that mutations that impair CD79A or CD79B ITAM function in mouse B cells lead to exaggerated antigenic responses 17, 22, 23 . Future research should investigate the potential role of antigenic stimulation and CD79A ITAM mutations in DLBCL biopsies and lines (case number in parenthesis). b, CD79B ITAM mutation frequencies in lymphoma biopsies. c, Mutant CD79A and CD79B isoforms increase surface IgM. The GCB DLBCL line BJAB was reconstituted with either wild-type or mutant CD79A/B proteins. Surface IgM is depicted relative to CD79 RNA levels, estimated with bicistronic expression of CD8. 'Synthetic' mutants were not observed in patient samples. d, CD79B mutations prevent downmodulation of surface BCR by BCR signalling. The ABC DLBCL line HBL-1 was reconstituted with wild-type or Y196H mutant CD79B and treated for 24 h with dimethylsulphoxide (DMSO) or dasatinib, a BCR signalling inhibitor. Surface IgM (mean fluorescence intensity; MFI) is depicted relative to the levels in cells with wild-type CD79B treated with DMSO. Results are shown as means 6 s.e.m. for two experiments. e, CD79B mutations inhibit Lyn kinase activity in ABC DLBCLs. The indicated ABC DLBCL lines were reconstituted with wild-type or Y196F mutant CD79B. Lyn kinase activity in immunoprecipitates (IP) was estimated by densitometric analysis of western blots (WB) as phospho-Lyn (using anti-phosphotyrosine antibody 4G10) relative to total Lyn. in chronic active BCR signalling and in the spontaneous BCR clustering that characterizes ABC DLBCLs. BCR clustering does not depend on the CD79B mutations ( Supplementary Fig. 11 ), suggesting that other mechanisms contribute to this aspect of chronic active BCR signalling.
We considered therapeutic strategies to exploit chronic active BCR signalling in ABC DLBCL. Dasatinib, a kinase inhibitor approved for the treatment of chronic myelogenous leukaemia, inhibits Src-family kinases and BTK 24 . Dasatinib killed ABC DLBCL lines that rely on chronic active BCR signalling but not the BCR-independent line OCI-Ly3 or GCB DLBCL lines (Fig. 4a) . A selective BTK inhibitor, PCI-32765 (ref. 25) , was also selectively toxic to cell lines with chronic active BCR signalling (Fig. 4a) . By contrast, all ABC DLBCL lines were sensitive to an IKK-b inhibitor. In BCR-dependent lines, dasatinib decreased the phosphorylation of IkB-a, Akt, ERK and Lyn, as well as total protein tyrosine phosphorylation and IKK activity ( Fig. 4b and Supplementary Fig. 12 ). Dasatinib toxicity may therefore be due to NF-kB inhibition, which causes apoptosis, and Akt/mTOR inhibition, which causes 'metabolic catastrophe' 26 . Indeed, rapamycin, an mTOR inhibitor, synergized with an IKK-b inhibitor in killing ABC DLBCL lines with chronic active BCR signalling ( Supplementary Fig. 13 ). Our studies suggest that the position of molecular lesions in the BCR and NF-kB signalling pathways could be used to guide the therapy of ABC DLBCL. ABC DLBCLs with wildtype CARD11 and chronic active BCR signalling might respond to a BTK inhibitor, such as PCI-32765, and possibly to inhibitors of Src-family kinases, PKC-b or Syk, in some cases. By contrast, CARD11-mutant tumours would need to be treated with agents that target downstream components of the NF-kB pathway such as IKK 27 . A precise delineation of which ABC DLBCL cases depend on chronic active BCR signalling awaits the development of predictive biomarkers and the results of clinical trials involving BCR signalling inhibitors.
METHODS SUMMARY
Cell lines possessing the ecotropic retroviral receptor and the tetracycline repressor were generated and used in RNA interference library screening, shRNA toxicity assays and cDNA complementation studies as described 4 . DLBCL cell lines were assigned to the ABC or GCB subtypes by gene expression profiling 4 (Supplementary Fig. 14) . shRNA screening results are given in Supplementary Tables  1 and 3, and shRNA sequences are listed in Supplementary Tables 2 and 3 . Specific shRNA-mediated mRNA and protein knockdown was documented (Fig. 2c and Supplementary Figs 6a and 15) . IKK reporter lines were engineered to express an IkB-a-Photinus luciferase fusion and Renilla luciferase 27 . TIRF imaging of the BCR was based on techniques described previously 12 . Tumour biopsies were obtained before treatment from patients with de novo DLBCL 28 , gastric MALT lymphoma and Burkitt's lymphoma. All samples were studied in accordance with a protocol approved by the National Cancer Institute Institutional Review Board.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
METHODS
Cell lines. All cell lines were maintained in a humidified 5% CO 2 incubator at 37 uC. Cell lines were grown in RPMI 1640 medium supplemented with glutamine, 2-mercaptoethanol, penicillin/streptomycin and 10% fetal bovine serum, except for OCI-Ly3 and OCI-Ly10, which were maintained in Iscove's modified Dulbecco's medium supplemented with 2-mercaptoethanol, penicillin/streptomycin and 20% heparinized human plasma. All cell lines had previously been modified to express an ecotropic retroviral receptor and a fusion protein of the Tet repressor and the blasticidin resistance gene, as described previously 4 . Retroviral transductions. Retroviral supernatants were prepared as described previously 5 . In brief, Lipofectamine 2000 (Invitrogen) was used to transfect 293T producer cells with a plasmid mixture for gag and pol, a mutant ecotropic env, and each particular retrovirus. After two days, supernatant was passed through a 0.45-mM filter, mixed with Polybrene (8 mg ml 21 ) and used for centrifugal transduction of target cells expressing the ecotropic retroviral receptor. In some instances a second infection was performed, using fresh supernatant collected three days after transfection of producer cells. shRNA library screening. shRNA library screening was performed as described 4 . The shRNA library was constructed in a pMSCV-based retroviral vector (pRSMX_Puro) with two expression cassettes, one for constitutive expression of a selectable marker (conferring puromycin resistance) and the other for inducible expression of shRNA, after release of binding of the bacterial tetracycline repressor by doxycycline (20 ng ml
21
). For the focused screen of BCR pathway genes ( Supplementary Fig. 5 ), the same procedure was applied except that the abundance of each shRNA was enumerated with an Illumina GAII sequencer. Comparison was made between an shRNA-uninduced sample from day 0 and an shRNA-induced sample from day 24 of culture. The magnitude and standard error of the shRNA effect were calculated by using a logistic regression model to estimate the relative probability that an shRNA was found in the shRNA-induced versus uninduced samples. This model included a normalization factor that was a constant for all genes from a given shRNA pool in a given experiment and including normal random effects representing gene by experiment interactions. Other shRNA vectors and shRNA sequences. Modifications were made to the puromycin resistance gene cassette in the pMSCV-based retroviral shRNA vector, including fusion of the puromycin resistance gene to enhanced green fluorescent protein (EGFP) (pRSMX_PuroGFP) as described previously 4 or replacement of the puromycin resistance gene with the Escherichia coli gene encoding inosine 59-monophosphate dehydrogenase (IMPDH) to allow selection in mycophenolic acid. shRNA sequences used in this study are presented in Supplementary Tables 2  and 3 . Expression vectors and cDNA mutagenesis or modification. Retroviral vectors for inducible cDNA expression were either pBMN-based (http://www.stanford. edu/group/nolan/plasmid_maps/pmaps.html) or pMSCV-based with the cDNA expressed from a doxycycline-inducible cytomegalovirus (CMV) promoter in which a binding site for the bacterial tetracycline repressor is inserted at the transcription start site (derived from pCDNA4/TO (Invitrogen)). All mutagenesis was performed with the QuikChange kit from Stratagene and verified by dye termination sequencing. Modification of the CD79A and CD79B cDNAs for the surface expression experiments shown in Fig. 4c -e included insertion of a Flag peptide coding sequence just downstream of the signal peptide cleavage site, and fusion to EGFP at the 39 end, after removal of the stop codon and addition of a six-amino-acid spacer as described previously 30 . 39 GFP fusions were also constructed for Syk (Supplementary Fig. 6b ). shRNA toxicity and complementation assays. The toxicity of individual shRNA sequences was chiefly tested with the PuroGFP vector as described previously 4 . In brief, after infection with a retrovirus expressing shRNA and GFP, FACS was used to determine the fraction of live cells that were GFP-positive two days after transduction. Doxycycline was then added to induce shRNA expression, and the fraction of GFP-positive live cells was determined at various intervals during subsequent culture. Parallel cultures were prepared with a vector expressing a control shRNA. The GFP-positive fraction from the test shRNA cultures was normalized both to the GFP-positive fraction from the control shRNA culture on the same day and to the GFP-positive fraction on day 2. For CD79B (Supplementary Fig. 2b, c) , adequate knockdown by shRNA required the selection of shRNA-and GFP-expressing single-cell clones by limiting dilution. Toxicity assays of these clones were performed by mixing the clones with untransduced cells and determining an initial GFP-positive fraction before the addition of doxycycline to induce shRNA expression. The fraction of GFP-positive cells at various time points was normalized to this initial value.
For complementation studies with CD79A ( Supplementary Fig. 9 ), OCI-Ly10 cells were infected with retroviruses expressing wild-type or mutant CD79A coding regions along with Lyt2 (mouse CD8). Subsequently, cells were infected with a retrovirus expressing a CD79A shRNA (targeting the 39 untranslated region (UTR)) and GFP and the fraction of Lyt2-positive/GFP-positive cells was monitored over time as above.
For complementation studies with CD79B ( Supplementary Fig. 9 ), HBL-1 cells were infected with a retrovirus expressing a CD79B shRNA (targeting the 39 UTR) and GFP, selected in puromycin, and single-cell cloned. A clone was selected with the best doxycycline-inducible knockdown of CD79B as assessed by FACS. This clone was infected with a retrovirus expressing a wild-type or mutant CD79B coding region along with Lyt2 (mouse CD8). These GFP-positive cells were mixed with unmodified HBL-1 cells and the fraction of GFP-positive/Lyt2-positive cells was monitored over time, as above.
To analyse the influence of the CD79B mutations on chronic active BCR signalling in ABC DLBCLs (Fig. 4d, e) , HBL1 or TMD8 cells were infected with a retroviral vector with doxycycline-inducible expression of an shRNA directed at the CD79B 39 UTR-directed and an IMPDH drug selection marker. After selection in mycophenolic acid, single-cell clones were assayed for doxycyclineinducible knockdown of CD79B by FACS. Clones were subsequently infected with a retrovirus expressing wild-type or mutant (Y196F) CD79B coding-region cDNAs from the MSCV LTR together with a hygromycin resistance gene. After selection in hygromycin, the CD79B shRNA was induced for three to five days before assay. BTK ASKA assay. BTK was modified by a 'gatekeeper' T474A mutation, as well as a second S538A mutation used previously to construct a BTK ASKA mutant 31 . Wild-type, kinase-dead (K430R) and ASKA forms of BTK were introduced as 39 GFP fusions without a selectable marker, and then the mixed (GFP-negative and GFP-positive) population was infected with a retrovirus expressing an shRNA targeting the BTK 39 UTR and selected with puromycin. The starting proportion of GFP-positive cells was determined by FACS with bead quantification, and then shRNA expression was induced with doxycycline in the presence or absence of the ASKA inhibitor 1NM-PP1 (2 mM; Sigma) for continued culture and periodic quantification. The increase in GFP-positive cells in the various cultures was normalized to the increase observed for wild-type BTK without 1NM-PP1. FACS assays for protein level. For quantification of most surface markers, FACS was performed by staining unfixed cells on ice. For quantification of CD79A, cells were fixed in 1.6% paraformaldehyde, permeabilized in methanol and stained with an antibody recognizing a peptide sequence in the intracellular domain (BD Biosciences). For analysis of total and surface-expressed levels of exogenous mutant CD79A or CD79B in the BJAB model system, and also their effect on surface IgM (Fig. 4c) , BJAB cells were first prepared to express an shRNA targeting either endogenous gene, using selected single clones in the case of CD79B, and then infected with bicistronic expression vectors containing 59 Flag-tagged and 39 GFP-tagged versions (described above) of the respective genes and an IRES-Lyt2 (murine CD8a) cassette. After induced knockdown of the endogenous proteins, three-colour FACS assays were performed in which GFP fluorescence was used as a measure of total exogenous protein, an Alexa-647 antibody against Lyt2 (BD Biosciences, excited with a He/Ne laser) was used as a marker of exogenous mRNA, and a phycoerythrin-conjugated antibody was used to detect surface expression of IgM (direct) or Flag (by secondary detection of unlabelled mouse anti-Flag (M2; Sigma). Western blotting. Control or doxycycline-treated cells were lysed for 30 min in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% Nonidet P40, 2 mM EDTA) supplemented with a cocktail of protease inhibitors (Roche) and phosphatase inhibitors (Sigma). Lysates were cleared by centrifugation at 15,000g at 4 uC for 10 min, and protein concentrations were determined by bicinchoninic acid protein assay (Pierce). Lysates (80-100 mg) were subjected to electrophoresis through a 4-12% Bis-Tris gel (Invitrogen) and immobilized on the nitrocellulose membranes. Proteins were detected by using the following antibodies: CD79A, Syk, IkB-a (Santa Cruz Biotechnology), BTK (ref. 32 ; provided by D. Stewart), phosphotyrosine (4G10; Millipore), Akt, ERK, p-Akt (S473), p-ERK (p44-T202, p42-Y204), b-actin, p-Lyn (Y507) and p-IkB-a (S32) (Cell Signaling Technology). Lyn immunoprecipitation and in vitro kinase assay. Cells were suspended at 10 7 cells ml 21 in PBS and lysed by mixing 1:1 (v/v) with RIPA buffer (0.5% Triton X-100, 0.5% deoxycholate, 0.05% SDS) in lysis buffer. Cells were lysed for 10 min on ice and then clarified by microcentrifugation (12,000g) for 20 min at 4 uC to yield a postnuclear supernatant. Lyn was immunoprecipitated from 0.5-1 ml of detergent extracts by incubation with 2 mg of anti-Lyn mouse monoclonal antibody H6 (Santa Cruz Biotechnology) for 1-2 h on ice and then rotated for 45 min with 35 ml of ImmunoPure Immobilized Protein A (Pierce) at 4 uC. Immunoprecipitates were washed twice with lysis buffer without detergent and then once with kinase assay buffer (20 mM Tris-HCl, pH 7.6, 10 mM MgCl 2 , 1 mM Na 3 VO 4 ). After being washed, Lyn immunoprecipitates were subjected to in vitro kinase assays by the addition of 200 ml of kinase assay buffer containing either 1 mM ATP or no ATP. Samples were then incubated at 37 uC for 15 min.
